BenevolentAI appoints new Chief Technology Officer
The experienced Dr James Malone has been named new CTO from the start of April and will be based in the UK. Dr Neil is leaving after seven years at the company to relocate closer to his family.
BenevolentAI is acknowledged as a leader in applying advanced AI to accelerate biopharma drug discovery.
The new man has more than 20 years’ experience in industry and academia, working across data engineering, AI and bioinformatics, as well as building and leading global engineering teams, largely to support biomedical R & D. Prior to joining BenevolentAI, Dr Malone was Vice-President of Engineering at Logically.ai and previously held senior leadership roles at AI life sciences companies BenchSci and SciBite.
At BenchSci, as VP Data Engineering, Machine Learning and Bioinformatics, he was involved in applying best practices in AI and data engineering into R & D, including drug safety and discovery.
As CTO at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data. Prior to this he was at the European BioInformatics Institute (EBI) working on a variety of data sources, such as Open Targets.
Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “On behalf of BenevolentAI, I want to thank Daniel Neil for his many achievements and dedication to the company over many years and wish him well for the future.
“We are excited to welcome James Malone to BenevolentAI as our new CTO. James’ extensive experience is aligned to the problems of drug discovery and development and AI approaches.
“Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
Dr Malone added: “I’m excited to join the leadership team at BenevolentAI. I believe the combination of the Benevolent PlatformTM, along with the company’s in-house scientific expertise, gives BenevolentAI strong foundations to continue to advance the use of AI in drug discovery and development to find life-changing treatments for patients.”